Portal de Periódicos da CAPES

Pituitary-Ovarian Responses to Nafarelin Testing in the Polycystic Ovary Syndrome

1989; Massachusetts Medical Society; Volume: 320; Issue: 9 Linguagem: Inglês

10.1056/nejm198903023200904

1533-4406

Randall B. Barnes, Robert L. Rosenfield, Stephen Burstein, David A. Ehrmann,

Sperm and Testicular Function

To investigate the basis of polycystic ovary syndrome, we examined the responses of patients to nafarelin, a specific gonadotropin-releasing-hormone agonist, given to stimulate pituitary and gonadal secretion. We compared 16 normal women in the follicular phase, 5 normal men, 8 women with polycystic ovary syndrome, and 1 woman with polycystic ovary syndrome caused by a 3β-hydroxysteroid dehydrogenase deficiency. After 100 μg of nafarelin was given subcutaneously, serum follicle-stimulating hormone and luteinizing hormone increased rapidly to peak levels within four hours. The women with polycystic ovary syndrome had a pattern similar to that of the men, with greater early luteinizing-hormone responses (30 minutes to 1 hour) and lower peak follicle-stimulating-hormone responses than normal women (P<0.05). Patients with polycystic ovary syndrome responded to gonadotropin stimulation with normal to increased production of plasma estrogens and increased levels of androstenedione at 16 to 24 hours (P<0.05). Elevated production of 17α-hydroxyprogesterone was found in all the women with polycystic ovary syndrome and in the men. These abnormal responses were unchanged by pretreatment with dexamethasone to suppress adrenal function. In the patient with the 3β-hydroxysteroid dehydrogenase deficiency, both basal and stimulated plasma levels of Δ5-3β-hydroxysteroids before the enzymatic block were elevated, whereas plasma levels of 17α-hydroxyprogesterone and androstenedione — the steroids immediately beyond the block — were low. We conclude that women with polycystic ovary syndrome have masculinized pituitary and ovarian responses to stimulation by nafarelin. Our findings suggest that the regulation of the ovarian 17-hydroxylase and C-17,20-lyase activities is abnormal in such women. (N Engl J Med 1989;320:559–65.)